HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IFF Says Probiotics Cool-Off Is ‘Understandable,’ Fine Fragrance Growth A Welcome Surprise

Executive Summary

Destocking of probiotics and vitamins as a result of softening consumer demand post-pandemic dragged on International Flavors & Fragrance’s Health & Biosciences business in the third quarter, while mid-teens growth in fine fragrance and fragrance ingredients drove 9% comparable sales growth for the New York firm’s Scent division, reported on 7 November.

You may also be interested in...



IFF Will Be Slimmer, Simplified And Better Aligned With End-Markets – CEO Clyburn

New York-based International Flavors and Fragrances is shooting for 4%-6% top-line growth in currency-neutral sales over the 2024-2026 period, versus 2%-3% today, through a long-term strategic transformation that will streamline operations while repositioning to meet customer needs better from a category perspective.

Coty ‘Advantaged’ In FY 2023 With Consumer Biz Momentum, Unflagging Luxury Fragrance Demand

Coty leadership says it has not seen any slowdown in fragrance “premiumization” trends, which bodes well for its booming Prestige business. Strong momentum in Consumer Beauty and a robust innovation pipeline across both divisions have the firm targeting 6%-8% like-for-like growth in fiscal 2023.

IFF’s ‘Differentiating’ R&D This Year Includes Probiotics, Biodegradable Fragrance; Q1 Sales Increase 13%

New York firm International Flavors & Fragrances Inc. aims to stand out in 2022 with an R&D pipeline that includes probiotics, plant-based protein and biodegradable fragrances, says CEO Frank Clyburn, speaking in his first quarterly earnings presentation since taking the helm in February.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel